Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication and its major protease in a non-competitive way

Chaves, Otávio Augusto; Sacramento, Carolina Q.; Fintelman-Rodrigues, Natalia; Temerozo, Jairo Ramos; Dutra, Filipe Pereira; Mizurini, Daniella M.; Monteiro, Robson Q.; Vazquez, Leonardo; Bozza, Patrícia Torres; Faria Neto, Hugo Caire Castro; Souza, Thiago Moreno L.

This article is a Preprint

Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.

Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication and its major protease in a non-competitive way

Chaves, Otávio Augusto; Sacramento, Carolina Q.; Fintelman-Rodrigues, Natalia; Temerozo, Jairo Ramos; Dutra, Filipe Pereira; Mizurini, Daniella M.; Monteiro, Robson Q.; Vazquez, Leonardo; Bozza, Patrícia Torres; Faria Neto, Hugo Caire Castro; Souza, Thiago Moreno L..

Affiliation

Chaves, Otávio Augusto; Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Centro de Desenvolvimento Tecnológico em Saúde. Instituto Nacional de Ciência e Tecnologia em Inovação em Doenças Negligenciadas. Rio de Janeiro, RJ, Brasil..

Preprint in En | PREPRINT-FIOCRUZ | ID: ppf-54672

Key words

Apixaban; Anticoagolante; Inibe a replicação do SARS-CoV-2; Via Oral; COVID-19; SARS-CoV-2 replication; Apixaban; Anticoagulant; Inhibits SARS-CoV-2 replication; COVID-19

Fulltext

Add to My VHL

XML

Search on Google